loader

Amplia Therapeutics Limited

ASX:ATX

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Featured Articles and Interviews
Press Releases

Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Tumour Response in Sixth Patient Triggers Additional Recruitment in Pancreatic Cancer Trial

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Interactive Chart

×